Orthocell has been granted patents for its CelGro® collagen rope in China and Hong Kong. The product is now patented in five countries.
The collagen rope, part of the CelGro collagen scaffold platform, is designed to augment ligament repair surgeries such as anterior cruciate ligament (ACL) reconstruction. First preclinical results in ACL repair are slated for release in 3Q21.
Managing Director Paul Anderson said, “There are currently no biological off-the-shelf solutions that mimic human ligament to enable the optimal repair of ACL injuries. The CelGro collagen rope addresses this problem, as it is designed to augment ACL reconstruction without the need to harvest the patient’s hamstring or patella tendon and will disrupt the sports injury repair market by dramatically improving ACL surgery outcomes.”
Orthocell has been granted patents for its CelGro® collagen rope in China and Hong Kong. The product is now patented in five countries.
The collagen rope, part of the CelGro collagen scaffold platform, is designed to augment ligament repair surgeries such as anterior cruciate ligament (ACL) reconstruction. First preclinical results in ACL...
Orthocell has been granted patents for its CelGro® collagen rope in China and Hong Kong. The product is now patented in five countries.
The collagen rope, part of the CelGro collagen scaffold platform, is designed to augment ligament repair surgeries such as anterior cruciate ligament (ACL) reconstruction. First preclinical results in ACL repair are slated for release in 3Q21.
Managing Director Paul Anderson said, “There are currently no biological off-the-shelf solutions that mimic human ligament to enable the optimal repair of ACL injuries. The CelGro collagen rope addresses this problem, as it is designed to augment ACL reconstruction without the need to harvest the patient’s hamstring or patella tendon and will disrupt the sports injury repair market by dramatically improving ACL surgery outcomes.”
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Copy to clipboard 
